(Q37275571)

English

Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial

scientific article published on 15 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial (English)

1 reference

Europe PubMed Central

19 August 2017

0 references

revascularization

1 reference

based on heuristic

inferred from title

coronary artery bypass surgery

1 reference

based on heuristic

inferred from title

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

coronary artery disease

1 reference

based on heuristic

inferred from title

Rodica Pop-Busui

object named as

Rodica Pop-Busui

9

0 references

Maria M. Brooks

object named as

Maria Mori Brooks

2

0 references

author name string

Richard G Bach

1

1 reference

Europe PubMed Central

19 August 2017

Manuel Lombardero

3

1 reference

Europe PubMed Central

19 August 2017

Saul Genuth

4

1 reference

Europe PubMed Central

19 August 2017

Thomas W Donner

5

1 reference

Europe PubMed Central

19 August 2017

Alan Garber

6

1 reference

Europe PubMed Central

19 August 2017

Laurence Kennedy

7

1 reference

Europe PubMed Central

19 August 2017

E Scott Monrad

8

1 reference

Europe PubMed Central

19 August 2017

Sheryl F Kelsey

10

1 reference

Europe PubMed Central

19 August 2017

Robert L Frye

11

1 reference

Europe PubMed Central

19 August 2017

BARI 2D Investigators

12

1 reference

Europe PubMed Central

19 August 2017

language of work or name

0 references

publication date

15 July 2013

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

128

1 reference

Europe PubMed Central

19 August 2017

8

1 reference

Europe PubMed Central

19 August 2017

785-794

1 reference

Europe PubMed Central

19 August 2017

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

6 September 2017

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

6 September 2017

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

6 September 2017

A randomized trial of therapies for type 2 diabetes and coronary artery disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

6 September 2017

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

6 September 2017

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

6 September 2017

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

6 September 2017

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

6 September 2017

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

6 September 2017

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

6 September 2017

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

6 September 2017

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

6 September 2017

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

6 September 2017

Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

26 June 2018

Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

3 September 2018

Thiazolidinediones and clinical outcomes in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

3 September 2018

Thiazolidinediones and cardiovascular outcomes in older patients with diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

3 September 2018

Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

3 September 2018

Angiographic and clinical outcomes of rosiglitazone in patients with type 2 diabetes mellitus after percutaneous coronary interventions: a single center experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

3 September 2018

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

3 September 2018

Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

3 September 2018

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

3 September 2018

Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

3 September 2018

The safety of rosiglitazone in the treatment of Type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816149

3 December 2018

Therapies for type 2 diabetes and coronary artery disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The rosiglitazone story--lessons from an FDA Advisory Committee meeting

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypotheses, Design, and Methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1161/CIRCULATIONAHA.112.000678

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37275571&oldid=1699126099"